Significant capital inflows and partnerships shape the biotech landscape. SpliceBio secured $135 million in a Series B round to advance gene therapy for Stargardt disease, engaging top strategic investors. Novo Nordisk inked an $812 million deal with Deep Apple Therapeutics to augment its obesity pipeline. Early-stage startups leverage AI adoption, with venture capital interest growing despite broader market uncertainties. Meanwhile, companies like 32 Biosciences raised $6 million to develop gut microbiome diagnostics, exemplifying the expanding scope of biotech innovation.